Free tool
FAERS Monitor: Crexont
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217186 or its brand name (Crexont, Carbidopa, Levodopa). Reports on generic versions are filed under their own applications.
Reports
5,848
Serious
3,390
58% of reports
Hospitalization
1,565
Death reported
622
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective659
- fall514
- hallucination512
- dyskinesia443
- tremor386
- nausea317
- dizziness306
- death296
- fatigue281
- gait disturbance275
- cough270
- parkinson^s disease263
- confusional state259
- somnolence258
- condition aggravated256
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 96 |
| 2005 | 92 |
| 2006 | 85 |
| 2007 | 107 |
| 2008 | 224 |
| 2009 | 122 |
| 2010 | 150 |
| 2011 | 141 |
| 2012 | 134 |
| 2013 | 31 |
| 2014 | 67 |
| 2015 | 121 |
| 2016 | 192 |
| 2017 | 408 |
| 2018 | 380 |
| 2019 | 293 |
| 2020 | 418 |
| 2021 | 299 |
| 2022 | 272 |
| 2023 | 194 |
| 2024 | 310 |
| 2025 | 1,044 |
| 2026 | 668 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,311 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyskinesiaSignal | 443 | 39.6 | 36.2 | 16,491 |
| hallucinationSignal | 512 | 24.6 | 22.6 | 11,528 |
| tremorSignal | 386 | 8.4 | 7.6 | 2,516 |
| confusional stateSignal | 259 | 5.8 | 5.1 | 1,023 |
| fallSignal | 514 | 5.6 | 5.1 | 1,946 |
| gait disturbanceSignal | 275 | 5.2 | 4.6 | 929 |
| somnolenceSignal | 258 | 4.6 | 4.1 | 733 |
| coughSignal | 270 | 3.5 | 3.1 | 477 |
| condition aggravatedSignal | 256 | 3.0 | 2.7 | 351 |
| dizzinessSignal | 306 | 2.2 | 2.0 | 206 |
| drug ineffective | 659 | 1.8 | 1.7 | 248 |
| nausea | 317 | 1.4 | 1.3 | 44 |
| fatigue | 281 | 1.3 | 1.2 | 20 |
| death | 296 | 1.2 | 1.1 | 14 |
| parkinson^s disease | 263 | 0.0 | 0.0 | 943,013 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.